Company intelligence / Profile preview

Swysh

Alberta, Canada

Ownership: Private
Development stage: Other

Overview

Swysh has developed more than 800 Cannabis sativa lines and extracts under a Health Canada research license and has conducted in vitro research to identify cannabinoid-rich extracts with potential activity against COVID‑19 and migraine, but there are no reported completed human clinical trial results yet.[1][6][4]

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small moleculePlant extract
Industry: Biotech

Partnerships

Asia Green BiotechnologyPathway RX

Beyond the preview

Go deeper on Swysh.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Swysh.

Explore the full profile